Issuer news

Pentixapharm Releases Interim Report for the Third Quarter of 2024 Loss of Pentixapharm Holding AG for the reporting period: €49k No revenue realized during the stub fiscal year…

DATRON AG publishes consolidated financial figures for the first 9 months of the 2024 financial year (German only) Umsatz TEUR 45.397 (Vorjahreswert TEUR 47.025) Auftragseingang…

US National Cancer Institute Starts Advanced Clinical Trial with PentixaFor 29.10.2024 / 11:46 CET Berlin and Würzburg, Germany, October 29, 2024 – The National Cancer Institute…

New offering for business mail now comes from the cloud – Digital transformation in output management (German only) 22.10.2024 / 09:30 CET Neues Produkt Binect ONE basiert…

EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor 18-Oct-2024 / 15:49 CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No…